HS-10542 / Jiangsu Hansoh Pharma - LARVOL DELTA

HS-10542 Study in Healthy Participants (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

New P1 trial

THE CLINICAL TRIAL APPROVAL FOR HS-10542 CAPSULES ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (Hansoh Pharma Press Release) - "The board of directors...of Hansoh Pharmaceutical Group Company Limited...is pleased to announce that, HS-10542 capsules, a Category 1 innovative drug self-developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China, which is intended to be investigated in clinical trials for paroxysmal nocturnal hemoglobinuria (PNH), and immunoglobulin A nephropathy (IgAN)."

New trial • IgA Nephropathy • Paroxysmal Nocturnal Hemoglobinuria